首页> 外文期刊>Clinical and Experimental Immunology: An Official Journal of the British Society for Immunology >Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
【24h】

Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

机译:血清microRNA作为原发性硬化性胆管炎和胆管癌的新型生物标志物

获取原文
获取原文并翻译 | 示例
       

摘要

The diagnosis of primary sclerosing cholangitis (PSC) is difficult due to the lack of sensitive and specific biomarkers, as is the early diagnosis of cholangiocarcinoma (CC), a complication of PSC. The aim of this study was to identify specific serum miRNAs as diagnostic biomarkers for PSC and CC. The levels of 667 miRNAs were evaluated in 90 human serum samples (30 PSC, 30 CC and 30 control subjects) to identify disease-associated candidate miRNAs (discovery phase). The deregulated miRNAs were validated in an independent cohort of 140 samples [40 PSC, 40 CC, 20 primary biliary cirrhosis (PBC) and 40 controls]. Receiver operating characteristic (ROC) curves were established and only miRNAs with an area under the curve (AUC)>070 were considered useful as biomarkers. In the discovery phase we identified the following: 21 miRNAs expressed differentially in PSC, 33 in CC and 26 in both in comparison to control subjects as well as 24 miRNAs expressed differentially between PSC and CC. After the validation phase, miR-200c was found to be expressed differentially in PSC versus controls, whereas miR-483-5p and miR-194 showed deregulated expression in CC compared with controls. We also demonstrate a difference in the expression of miR-222 and miR-483-5p in CC versus PSC. Combination of these specific miRNAs further improved the specificity and accuracy of diagnosis. This study provides a basis for the use of miRNAs as biomarkers for the diagnosis of PSC and CC.
机译:由于缺乏敏感性和特异性的生物标志物,难以诊断原发性硬化性胆管炎(PSC),以及早期诊断为PSC并发症的胆管癌(CC)。这项研究的目的是确定特定的血清miRNAs作为PSC和CC的诊断生物标志物。在90个人类血清样本(30个PSC,30个CC和30个对照组)中评估了667个miRNA的水平,以鉴定与疾病相关的候选miRNA(发现期)。在一个独立的队列中,对140份样品[40 PSC,40 CC,20例原发性胆汁性肝硬化(PBC)和40例对照]进行了验证,验证了解除调节的miRNA。建立了接收者操作特征(ROC)曲线,并且只有曲线下面积(AUC)> 070的miRNA被认为是有用的生物标记。在发现阶段,我们确定了以下几项:与对照组相比,PSC中有21种miRNA差异表达,CC中有33项,CC中有26项,PSC与CC之间有24项miRNA差异表达。在验证阶段之后,发现miR-200c在PSC中与对照差异表达,而miR-483-5p和miR-194与对照相比在CC中表达失控。我们还证明了CC和PSC中miR-222和miR-483-5p的表达差异。这些特异性miRNA的组合进一步提高了诊断的特异性和准确性。这项研究为使用miRNAs作为诊断PSC和CC的生物标志物提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号